Mepolizumab Compositions for Deamidation, Oxidation, and Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions for mepolizumab, a monoclonal antibody that binds to interleukin 5 (IL-5), face challenges in maintaining critical quality attributes such as deamidation, oxidation, and aggregation, which affect its biological function and efficacy in treating IL-5 mediated diseases.
Innovation Solution
Compositions comprising antibodies with specific heavy and light chain amino acid sequences, with defined percentages of deamidated, oxidized, and aggregated variants, and formulated at a pH of 6.8 to 7.2 with buffering agents like histidine, phosphate, or citrate, to maintain optimal biological function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mepolizumab is formulated and stored, then it maintains biological activity and efficacy, but deamidation, oxidation, and aggregation occur which compromise quality attributes
Solution Approach 1:
The patent applies parameter changes by precisely controlling and specifying the pH range (6.8 to 7.2) and the percentages of deamidated, oxidized, and aggregated variants in the mepolizumab composition. By defining these parameters within specific ranges, the patent ensures that the composition maintains both biological function and quality stability, resolving the contradiction between reliability and compositional stability.
2Productivity
If mepolizumab compositions are developed, then treatment efficacy is achieved, but maintaining specific levels of variants requires precise control
Solution Approach 1:
The patent implements feedback mechanisms by establishing specific target ranges for deamidated (≤25%), oxidized (≤55%), and aggregated (≤20%) variants, and by controlling pH (6.8 to 7.2). These predefined specifications serve as feedback criteria during manufacturing and quality control, enabling precise control of variant levels while maintaining treatment efficacy.
3Reliability
If the antibody structure is optimized for binding, then biological activity is enhanced, but Fc effector functions are not activated due to lack of membrane-bound forms
Solution Approach 1:
The patent applies local quality by focusing the optimization on specific regions of the antibody molecule - the complementarity determining regions (CDRs) for IL-5 binding and the Fc region for FcRn binding. By locally optimizing these specific domains rather than the entire antibody structure, the patent achieves enhanced binding activity while maintaining the natural mechanism of action that does not require membrane-bound forms.
Data Source
AI summary
The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.